Bildkälla: Stockfoto

Cantargia: New Externally Funded Trial - Redeye

Redeye is optimistic about Cantargia’s new clinical trial of nadunolimab in acute myeloid leukaemia and myelodysplastic syndrome.

Redeye is optimistic about Cantargia’s new clinical trial of nadunolimab in acute myeloid leukaemia and myelodysplastic syndrome.
Börsvärldens nyhetsbrev
ANNONSER